Best Growth Stocks to Buy for September 22nd

Zacks highlighted ATI, KE Holdings and Centene as Zacks Rank #1 growth stocks, citing upward revisions to current-year consensus EPS estimates of 12.1%, 10.2% and 40.9%, respectively, over the past 60 days. The article is analyst-driven stock-selection commentary rather than new company disclosures, with limited expected broad market impact.

Analysis

This is a low-information catalyst: a quantitative ranking and estimate revisions can attract short-horizon retail flow, but neither establishes the durability, source, or cash-conversion quality of the revisions. The actionable distinction is whether revisions are driven by revenues, operating leverage, or one-time items; absent that attribution, chasing a same-day move has poor expected value. Treat the named quantum narrative as promotional rather than a read-through for MSFT, GOOG, AMZN, ORCL, META, NVDA, TSLA, or QUBT.

ATI is the most plausible fundamental follow-through candidate if revision momentum reflects aerospace/defense mix and pricing rather than quarterly timing. Its specialty-materials exposure creates operating leverage, but the same mechanism makes it vulnerable to aircraft-build-rate delays, titanium input inflation, and a reversal in widebody demand; the next earnings release and 2026 aerospace guidance are the relevant 1-3 month validation points.

CNC's unusually large estimate revision warrants diligence rather than immediate conviction: managed-care earnings can be reset sharply by medical-cost trends, risk-adjustment accruals, Medicaid redetermination effects, and state-rate adequacy. A sustained recovery requires evidence that the medical-loss-ratio trajectory and reimbursement assumptions support forward-year margins; otherwise, a headline revision can produce a short-lived multiple bounce. BEKE remains principally a China housing-policy and transaction-volume trade, so earnings estimates are secondary to resale volumes, mortgage policy, and developer confidence over the next 6-18 months.

Contrarian view: the market may overpay for a generic "growth" basket while missing that ATI, CNC, and BEKE have unrelated macro sensitivities. The cleaner expression is selective, catalyst-backed exposure rather than a broad long in analyst-revision names; there is no investable quantum-computing signal in the supplied evidence.

Key Decisions for Investors

• Watch ATI for a post-results entry rather than buying on the ranking: initiate a 1-3 month long only if management reaffirms or raises aerospace/defense volume and margin outlook and consensus FY EPS continues to move higher. Target 10-15% upside on multiple stability plus revisions; exit on a guidance cut, material aerospace delivery deferral, or margin compression from input costs.
• Keep CNC on an earnings-alert list, not a preemptive long. Go long for a 3-6 month recovery only if medical-cost guidance, state reimbursement commentary, and cash conversion corroborate the estimate reset; a failure to demonstrate medical-loss-ratio stabilization would favor avoiding the name or pairing a CNC short against a diversified managed-care long.
• Use BEKE only as a tactical China-property policy vehicle: consider a small 1-3 month long after independently confirmed improvement in existing-home transactions and mortgage easing, preferably paired against a broad China equity ETF to isolate housing beta. Limit risk tightly because renewed developer stress or weak resale activity can overwhelm estimate momentum.
• Do not add exposure to QUBT or hyperscalers on the quantum-computing promotion. Reassess only on disclosed commercial bookings, capex commitments, or material revenue guidance; absent those, any price response is narrative-driven and vulnerable to rapid reversal.